



INVEST INDIA

Special Incentives for your Pharmaceuticals Journey in India

*Production Linked Incentive Scheme 2.0
Financial Incentives over \$2 Bn*



Applications Close on 31st July, 2021



Department of Pharmaceuticals
Ministry of Chemicals & Fertilizers
Government of India

www.investindia.gov.in
pharma@investindia.org.in
+91-9324079706



INVEST INDIA

The India Story



Jumped 79 places from 142nd to 63rd rank on **World Bank's Ease of Doing Business**




FDI rose by **13%** while the global FDI fell by **42%** in FY19-20



Corporate income tax is the lowest in South Asia at **17%**


■ Nominal GDP (in \$Tn)

\$8-9 Tn in the next 3 yrs




Pharma in India

Market Size & Growth



Export Market (\$Bn)



FDI Inflow Has grown from \$518 Mn in 2020 to \$1,490 Mn in 2021 at a CAGR of 205.56%

Key Growth Drivers



Increase in budget allocation to health and wellbeing from \$12,939 Mn to **\$30,664 Mn** an increase of **137%**



Non-Communicable Diseases are expected to cost **\$4.58 Tn** (2012-2030)



Elderly population to increase from 8.5% in 2016 to **21% in 2050**

PLI Scheme 2.0 - Snapshot

**INR 15,000 Cr
(Over \$2 Bn)
Financial Outlay**

**FY21-FY29
Tenure of the scheme**

**INR 1,200 Cr
(\$164 Mn)
Maximum Incentive[#]**

What Group You Fall In



- Maximum applicants to be selected (Maximum Foreign MNCs applicants permitted)
- Total incentive allocated to the group
- Minimum Cumulative Investment per participant till FY 2025-26
- Incentive ceiling per applicant[#]

What Counts As Investments : On/After 1st April, 2020.

Plant, Machinery, Equipment and Associated Utilities

Research & Development Expenditure

Transfer of Technology Agreements

Product Registration

Building^{##}

*Consolidated Global Revenues of the applicant and Group Company, if any, from the manufacturing of pharmaceutical goods. Revenues from any other source for instance R&D services, rental incomes, etc., shall be excluded for calculating the GMR.

** Also includes MSME segment which has different criteria for Investments and Incentives. Details covered in operational guidelines of the scheme.

Not an entitlement


Conditions Apply

Incentives You Get

Net incremental Sales of Eligible Product

X

% of Incentive



Category 1 Bio-pharmaceuticals, Complex Generic Drugs, Patented Drugs. Drugs nearing Patent Expiry, Cell Based or Gene Therapy drugs

Category 2 includes KSMs, APIs, drug intermediates except PLI 1.0 products

Category 3 includes repurposed drugs, auto immune drugs, anti-cancer drugs, anti-diabetic drugs, anti-infective drugs, cardiovascular drugs and anti-retroviral drugs

How You Will Be Evaluated

Group A & B



Group C

Investments# in last 10 years

No. of ANDAs/NDAs*

Investments# in last 10 years

No. of ANDAs/NDAs*



R&D expenditure (% of GMR from pharma in FY18-FY20)

GMR from pharma in FY2019-20


*USFDA / EDQM / UK MHRA / PMDA / Health Canada / TGA as on 01.04.2021.

Gross manufacturing Investment



INVEST INDIA

BECOME A GLOBAL CHAMPION NOW



Scan to Apply

Applications Close on 31st July, 2021

Write to us at : pharma@investindia.org.in

Know more at : <https://www.investindia.gov.in/schemes-for-pharmaceuticals-manufacturing>



Department of Pharmaceuticals
Ministry of Chemicals & Fertilizers
Government of India

www.investindia.gov.in
pharma@investindia.org.in
+91- 9324079706



INVEST INDIA